Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723198 | 0.76 | — | — | |
| SCHEMBL22781257 | 0.75 | — | — | |
| SCHEMBL11982030 | 0.75 | CYP2D6 (0.69) | CYP2D6KDM4E | |
| SCHEMBL7865959 | 0.74 | TSHR (0.32) | — | |
| Hydrochloric Acid SCHEMBL18339801 | 0.73 | CYP2D6 (0.39) | CYP2D6KDM4E | |
| SCHEMBL15027010 | 0.72 | — | — | |
| SCHEMBL18681569 | 0.72 | CYP2D6 (0.36) | CYP2D6KDM4E | |
| SCHEMBL23682214 | 0.72 | — | — | |
| SCHEMBL20261079 | 0.72 | CYP2D6 (0.41) | CYP2D6 | |
| SCHEMBL19502412 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024124143-A2 | HSC TARGETED LNP FOR DELIVERY OF PRO-APOPTOTIC MRNA AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024112882-A1 | TARGETED DELIVERY OF GENE EDITING CONSTRUCTS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024086614-A2 | TARGETED LNP-MRNA WITH MINIMAL OFF-TARGET EXPRESSION AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2023086830-A1 | INTRASPINAL DELIVERY OF THERAPEUTIC AGENTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023076977-A1 | NOROVIRUS VACCINE AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023023589-A2 | MRNA VACCINES AGAINST TICK SALIVARY PROTEINS, AND METHODS OF USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022232514-A1 | COMPOSITIONS AND METHODS FOR TARGETING LIPID NANOPARTICLE THERAPEUTICS TO STEM CELLS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022081699-A1 | IN VIVO TARGETING OF T CELLS FOR MRNA THERAPEUTICS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081702-A1 | IN VIVO TARGETING OF CD4+-T CELLS FOR MRNA THERAPEUTICS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081694-A1 | IN VIVO TARGETING OF FIBROSIS BY ANTI-CD5-TARGETED FAP-CAR T MRNA-LNP | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021202734-A2 | UNIVERSAL INFLUENZA VACCINE USING NUCLEOSIDE-MODIFIELD MRNA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021202836-A1 | FACTOR B INHIBITORS AND USES THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021150891-A1 | THE USE OF GROWTH FACTOR-ENCODING NUCLEOSIDE-MODIFIED MRNA FOR PERIODONTAL TISSUE AND BONE REGENERATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-07-29 | — | — | WO | disclosed |
| EP-3766916-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics Inc. (CA) | 2021-01-20 | — | — | EP | disclosed |
| WO-2018132537-A1 | NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN IMMUNE RESPONSE AGAINST ZIKA VIRUS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-07-19 | — | — | WO | disclosed |
| WO-2018107026-A1 | DELIVERY OF TARGET SPECIFIC NUCLEASES | SANGAMO THERAPEUTICS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018081638-A1 | NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018078053-A1 | LIPID NANOPARTICLE MRNA VACCINES | CUREVAC AG (DE) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018081480-A1 | LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2018-05-03 | — | — | WO | disclosed |
| WO-2015199952-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC. (CA) | 2015-12-30 | — | — | WO | disclosed |